Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 5/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 5/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.38 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24427976 | 0.87 | CYP17A1 (0.42) | AAK1CYP17A1KCNQ4KCNQ5MEN1 | |
| SCHEMBL28459659 | 0.84 | CYP17A1 (0.40) | AAK1CYP17A1KCNQ4KCNQ5MEN1 | |
| SCHEMBL30038713 | 0.84 | CYP17A1 (0.40) | AAK1CYP17A1KCNQ4KCNQ5MEN1 | |
| SCHEMBL24427982 | 0.83 | CYP17A1 (0.40) | AAK1CYP17A1KCNQ4KCNQ5MEN1 | |
| SCHEMBL21468506 | 0.82 | KCNQ4 (0.40) | AAK1CYP17A1KCNQ4KCNQ5MEN1 | |
| SCHEMBL7008829 | 0.81 | CYP17A1 (0.44) | KCNQ3KCNQ2AAK1CYP17A1KCNQ4 | |
| SCHEMBL22684078 | 0.81 | CYP17A1 (0.38) | AAK1CYP17A1KCNQ4KCNQ5MEN1 | |
| SCHEMBL30126132 | 0.80 | CYP17A1 (0.40) | AAK1CYP17A1KCNQ4KCNQ5MEN1 | |
| SCHEMBL29909461 | 0.79 | RXFP1 (0.46) | AAK1CYP17A1KCNQ4KCNQ5MEN1 | |
| SCHEMBL575004 | 0.79 | RXFP1 (0.46) | AAK1CYP17A1KCNQ4KCNQ5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| CN-111601799-B | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| CN-111601799-A | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2020-08-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | IL17A, IL2, IL23R | KCNQ3 2343/4885KCNQ2 1620/4885AAK1 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.